Research
Mixed
Noninvasive tests (FIB-4, ELF, MRE) are recommended for screening and risk stratification of MASLD, with FIB-4 as the first-line assessment due to its simplicity and cost-effectiveness.
If you have metabolic risk factors like obesity or type 2 diabetes, ask your doctor for a FIB-4 score. It is a simple, low-cost calculation using age, AST, ALT, and platelet count that helps identify liver fibrosis risk early.
GoodSupportsHIGH confidence
A multistep approach is recommended in adult patients with MASLD, wherein first FIB-4 should be used by practitioners due to its simplicity, low cost, and widespread availability.
Why this rating
Based on a modified Delphi consensus of 15 experts using GRADE criteria, supported by multiple cited studies.
Source
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
Faisal Abaalkhail et al. · Saudi Journal of Gastroenterology · 2025
DOI 10.4103/sjg.sjg_199_25
clinical_guideline · n=15Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →